Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis

For the first time, Eupraxia is reporting 24-week data on symptom response from the highest dose cohort in the open label, Phase 1b/2a portion of the RESOLVE trial. The data ...

Eupraxia Pharmaceuticals Posts Strong Six-Month EoE Data for EP-104GI as RESOLVE Trial Advances

Detailed price information for Eupraxia Pharmaceuticals Inc (EPRX-Q) from The Globe and Mail including charting and trades.

Oral cancer to diabetes: 7 dangerous diseases your mouth reveals early; dentist’s warning you can’t ignore

Your mouth can reveal early signs of serious diseases like diabetes, anemia, vitamin B12 deficiency, acid reflux, HIV, oral cancer, and Sjögren’s syndrome. Experts say subtle changes in colour, ...